Cell Therapy News/Articles, page-217

"I get it.. you feel that until MSB has revenue it is too speculative to assign a value."

Yep.
Can you assign a value to it, along with some half-cogent substantiation for that value?


"What I'm interested in knowing is what current spec end stock meets your rigorous requirements?? i.e priced like a spec, with the revenue of CSL. Please let me know - keen to jump in there with you mate."

No, I can't.
For the very reason that I'm not sure why you feel that buying a stock that is "priced like a spec, with the revenue of CSL" is a necessary and sufficient condition for successful investing.

Why, to cite your very example of CSL, that stock has not been priced like a "spec" for decades and yet there has been ample opportunity over time for people to by that stock - at strictly non-spec prices - and they would have become quite wealthy in the process.

In fact, when I first started posting on MSB, some people - great MSB exponents, they were (and, indeed, still are) - were exhorting me to not buy the existing CSL, but to buy the next CSL (i.e., MSB).

The rest, as they say, is history.